Stockscreener 앱 받기
8.05
1.51%
0.12
시간 외 거래:
8.05
전일 마감가:
$7.93
열려 있는:
$7.96
하루 거래량:
211.15K
Relative Volume:
0.39
시가총액:
$429.68M
수익:
$27.46M
순이익/손실:
$-46.05M
주가수익비율:
-6.2403
EPS:
-1.29
순현금흐름:
$-33.83M
1주 성능:
-0.74%
1개월 성능:
-5.07%
6개월 성능:
+22.15%
1년 성능:
+39.76%
1일 변동 폭
$7.90
$8.09
1주일 범위
$7.61
$8.2155
52주 변동 폭
$4.20
$9.76
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
명칭
Zevra Therapeutics Inc
전화
(321) 939-3416
주소
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
ZVRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
8.05 | 429.68M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-08 | 재개 | Cantor Fitzgerald | Overweight |
| 2024-10-07 | 개시 | Guggenheim | Buy |
| 2024-09-24 | 개시 | JMP Securities | Mkt Outperform |
| 2024-09-24 | 재확인 | Maxim Group | Buy |
| 2024-04-02 | 재확인 | Maxim Group | Buy |
| 2024-03-12 | 개시 | William Blair | Outperform |
| 2023-03-17 | 개시 | Maxim Group | Buy |
모두보기
Zevra Therapeutics Inc 주식(ZVRA)의 최신 뉴스
Barclays PLC Buys 42,926 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
Barclays PLC Has $399,000 Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Positive Signs As Multiple Insiders Buy Zevra Therapeutics Stock - Yahoo Finance
Cantor Fitzgerald Weighs in on ZVRA FY2024 Earnings - Defense World
Learn to Evaluate (ZVRA) using the Charts - Stock Traders Daily
FY2024 EPS Forecast for Zevra Therapeutics Raised by Analyst - MarketBeat
Zevra Therapeutics (NASDAQ:ZVRA) Coverage Initiated at Cantor Fitzgerald - Defense World
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Bought by Barclays PLC - Defense World
Geode Capital Management LLC Has $7.25 Million Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
Geode Capital Management LLC Boosts Stock Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
(ZVRA) Technical Pivots with Risk Controls - Stock Traders Daily
Sanctuary Advisors LLC Trims Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
Sanctuary Advisors LLC Has $194,000 Stock Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
State Street Corp Has $5.36 Million Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Analysts Expect Breakeven For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Before Long - Yahoo Finance
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Analysts Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Target Price at $21.00 - MarketBeat
13,551 Shares in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Bought by XTX Topco Ltd - Defense World
(ZVRA) Investment Analysis and Advice - Stock Traders Daily
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Position Increased by Charles Schwab Investment Management Inc. - Defense World
Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024 - The Manila Times
Zevra Therapeutics Secures Coveted Spot in Nasdaq Biotechnology Index Following Transformative Year - StockTitan
Zevra Therapeutics' SWOT analysis: rare disease drug maker's stock poised for growth - Investing.com
Fmr LLC Acquires 2,312,384 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
Zevra Therapeutics Restructures to Focus on Rare Diseases - MSN
A drug for fewer than 1,000 patients? Awareness and diagnosis are key. - PharmaVoice
Zevra Therapeutics Announces Organizational Changes - The Manila Times
Zevra Therapeutics, Inc. Announces Departure of Executives - Marketscreener.com
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has caught the attention of institutional investors who hold a sizeable 42% stake - Yahoo Finance
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $21.00 Consensus Price Target from Brokerages - MarketBeat
Vestal Point Capital LP Purchases Shares of 525,000 Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
179,874 Shares in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Purchased by Propel Bio Management LLC - MarketBeat
Zevra Therapeutics to Participate at Upcoming Investor Conferences - The Manila Times
Zevra Therapeutics CEO to Present at Major Healthcare Investment Conferences | ZVRA Stock News - StockTitan
Zevra Therapeutics (NASDAQ:ZVRA) Reaches New 52-Week HighShould You Buy? - MarketBeat
Zevra Therapeutics Launches MIPLYFFA for Niemann-Pick Disease - Yahoo Finance
ZVRA stock touches 52-week high at $9.6 amid robust growth - Investing.com UK
Equities Analysts Set Expectations for ZVRA FY2024 Earnings - MarketBeat
Zevra launches first FDA-approved NPC treatment By Investing.com - Investing.com Australia
Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C - The Manila Times
Zevra launches first FDA-approved NPC treatment - Investing.com India
HC Wainwright Has Negative Forecast for ZVRA FY2028 Earnings - MarketBeat
Zevra Therapeutics (NASDAQ:ZVRA) Earns "Buy" Rating from HC Wainwright - MarketBeat
Guggenheim Initiates Coverage of Zevra Therapeutics (ZVRA) with Buy Recommendation - MSN
Zevra Therapeutics (STU:1GDA) Enterprise Value : €424.12 Mil (As of Nov. 20, 2024) - GuruFocus.com
Zevra Therapeutics Q3 2024 Earnings Preview - MSN
Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates - MSN
Zevra Therapeutics Inc (ZVRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.65%
4.62%
자본화:
|
볼륨(24시간):